StreetInsider.com

New study identifies potential therapeutic target for stomach cancer


Get instant alerts when news comes in about your stocks. Request a one-week free trial to StreetInsider Premium over here.


WASHINGTON, June 6, 2022 (The Globe Newswire) — A recently published article in Experimental Biology and Medicine (Volume 247, No. 10, May 2022) identifies a potentially important personalized treatment for stomach cancer. The study, led by Dr. Guohua Wang at the Private Institute of Environmental Medicine at Nantong University (China), indicates that blocking Musashi-1 expression reduces stomach cancer drug tolerance to chemotherapy.

Gastric cancer is a common gastrointestinal malignancy and ranks second in cancer-related deaths. Drug resistance is responsible for most deaths from stomach cancer. Musashi-1 (MSI1) is an RNA-binding protein that is a marker of gastric and intestinal stem cells and may serve as a biomarker and therapeutic target for gastric cancer. An early event in gastric cancer formation is the proliferation of MSI1-positive cells. Therefore, the authors hypothesized that a clear understanding of the role of MSI1 in gastric cancers may lead to more effective therapies for treating gastric cancer.

In this study, Dr. Wang and colleagues used immunohistochemistry to show that MSI1 expression in tumor samples was significantly greater than in adjacent normal tissues. Furthermore, MSI1 levels are consistent with both patient outcomes and expression of important indicators of cell division; Inhibition of MSI1 increased the effectiveness of chemotherapy drugs used to treat gastric cancer. Their study provides new insight into the potential application of personalized treatment for gastric cancer and may help predict the chemosensitivity of cancer and develop more effective gene-guided prodrug therapy.

Dr. Wang said, “We investigated the relationship between Musashi-1 (MSI1) expression and the efficacy of chemotherapy drugs in gastric cancer to provide data that may support future clinical trials. Using MSI1 upregulation and downregulation in cell systems, we found that MSI1 modulates proliferation, migration and invasion and thus Likely to play a major role in the development and progression of gastric cancer Experiments using PDX mouse models showed that MSI1 inhibition reduces stomach cancer tolerance to chemotherapy si-MSI1 combined with chemotherapy The drugs were effective in reducing tumor sizes MSI1 likely affects the effect of treatment chemotherapy through the epicardial vascular substance (BVES) pathways, which are thought to be involved in cell adhesion and motility. Our study provides a strategy for developing personalized therapy for patients with gastric cancer and offers potential value in predicting chemosensitivity in tumors.”

Dr. Stephen R. Goodman, Editor-in-Chief, Department of Experimental Biology and Medicine, said, “Wang and colleagues presented an elegant study, demonstrating that MSI1 reduces gastric cancer drug tolerance by modulating the epicardial substance signaling pathway (BVES). These should provide Baseline studies for future clinical trials using combination therapy with Si-MSI1.”

Experimental biology and medicine It is an international journal dedicated to publishing interdisciplinary and interdisciplinary research in the biomedical sciences. The journal was first created in 1903. Experimental Biology and Medicine is the journal of the Society for Experimental Biology and Medicine. To learn about the benefits of community membership, visit www.sebm.org. If you are interested in publishing in the journal, please visit http://ebm.sagepub.com.

For more information please contact [email protected].

Related Images

picture 1

This content has been released through the press release distribution service on Newswire.com.

  • Featured image of experimental biology and medicine

Featured image of experimental biology and medicine

Featured image of experimental biology and medicine

Source: Experimental Biology and Medicine



2022-06-06 14:01:14

Leave a Comment

Your email address will not be published.